Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study

Ki Yeol Kim, Inho Cha, Joong Bae Ahn, Namkyu Kim, SunYoung Rha, Hyuncheol Chung, Jae Kyung Roh, Sang Joon Shin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose Adjuvant chemotherapy has been known as a standard treatment for patients with resected colon cancer. However, in elderly colon cancer patients, the characteristics of patients are heterogeneous with regard to life expectancy and comorbidities. Thus, with regard to the effectiveness of adjuvant chemotherapy for colon cancer, it is difficult to extrapolate data of clinical trials from the younger into the older general population. Methods Data for 382 elderly colon cancer patients were analyzed: 217 in Stage II and 165 in Stage III. The efficacy of adjuvant chemotherapy was evaluated in elderly colon cancer patients after a match by the propensity score method. Results For matched patients with Stage II colon cancer, there was no significant efficacy of adjuvant chemotherapy in the risk of death during all follow-up periods (P-value, 0.06-0.37). Though there was a tendency that the aadjuvant chemotherapy reduces the death rate during the follow-up periods, it was not statistically significant. In the case of Stage III, the adjuvant chemotherapy was significantly effective in matched patients for 5-year (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.30-0.90) and overall survival (HR, 0.56; 95% CI, 0.34-0.94). Conclusions Adjuvant chemotherapy for elderly patients with Stage II colon cancer is not effective, whereas elderly patients with Stage III with adjuvant chemotherapy appear to have a better survival rate in the general population.

Original languageEnglish
Pages (from-to)613-618
Number of pages6
JournalJournal of Surgical Oncology
Volume107
Issue number6
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Adjuvant Chemotherapy
Colonic Neoplasms
Observational Studies
Confidence Intervals
Propensity Score
Life Expectancy
Population
Comorbidity
Survival Rate
Clinical Trials
Drug Therapy
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

@article{27a47d3e33b44c4e9f87aa8300cd6297,
title = "Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study",
abstract = "Purpose Adjuvant chemotherapy has been known as a standard treatment for patients with resected colon cancer. However, in elderly colon cancer patients, the characteristics of patients are heterogeneous with regard to life expectancy and comorbidities. Thus, with regard to the effectiveness of adjuvant chemotherapy for colon cancer, it is difficult to extrapolate data of clinical trials from the younger into the older general population. Methods Data for 382 elderly colon cancer patients were analyzed: 217 in Stage II and 165 in Stage III. The efficacy of adjuvant chemotherapy was evaluated in elderly colon cancer patients after a match by the propensity score method. Results For matched patients with Stage II colon cancer, there was no significant efficacy of adjuvant chemotherapy in the risk of death during all follow-up periods (P-value, 0.06-0.37). Though there was a tendency that the aadjuvant chemotherapy reduces the death rate during the follow-up periods, it was not statistically significant. In the case of Stage III, the adjuvant chemotherapy was significantly effective in matched patients for 5-year (hazard ratio [HR], 0.69; 95{\%} confidence interval [CI], 0.30-0.90) and overall survival (HR, 0.56; 95{\%} CI, 0.34-0.94). Conclusions Adjuvant chemotherapy for elderly patients with Stage II colon cancer is not effective, whereas elderly patients with Stage III with adjuvant chemotherapy appear to have a better survival rate in the general population.",
author = "Kim, {Ki Yeol} and Inho Cha and Ahn, {Joong Bae} and Namkyu Kim and SunYoung Rha and Hyuncheol Chung and Roh, {Jae Kyung} and Shin, {Sang Joon}",
year = "2013",
month = "5",
day = "1",
doi = "10.1002/jso.23290",
language = "English",
volume = "107",
pages = "613--618",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "6",

}

Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. / Kim, Ki Yeol; Cha, Inho; Ahn, Joong Bae; Kim, Namkyu; Rha, SunYoung; Chung, Hyuncheol; Roh, Jae Kyung; Shin, Sang Joon.

In: Journal of Surgical Oncology, Vol. 107, No. 6, 01.05.2013, p. 613-618.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study

AU - Kim, Ki Yeol

AU - Cha, Inho

AU - Ahn, Joong Bae

AU - Kim, Namkyu

AU - Rha, SunYoung

AU - Chung, Hyuncheol

AU - Roh, Jae Kyung

AU - Shin, Sang Joon

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Purpose Adjuvant chemotherapy has been known as a standard treatment for patients with resected colon cancer. However, in elderly colon cancer patients, the characteristics of patients are heterogeneous with regard to life expectancy and comorbidities. Thus, with regard to the effectiveness of adjuvant chemotherapy for colon cancer, it is difficult to extrapolate data of clinical trials from the younger into the older general population. Methods Data for 382 elderly colon cancer patients were analyzed: 217 in Stage II and 165 in Stage III. The efficacy of adjuvant chemotherapy was evaluated in elderly colon cancer patients after a match by the propensity score method. Results For matched patients with Stage II colon cancer, there was no significant efficacy of adjuvant chemotherapy in the risk of death during all follow-up periods (P-value, 0.06-0.37). Though there was a tendency that the aadjuvant chemotherapy reduces the death rate during the follow-up periods, it was not statistically significant. In the case of Stage III, the adjuvant chemotherapy was significantly effective in matched patients for 5-year (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.30-0.90) and overall survival (HR, 0.56; 95% CI, 0.34-0.94). Conclusions Adjuvant chemotherapy for elderly patients with Stage II colon cancer is not effective, whereas elderly patients with Stage III with adjuvant chemotherapy appear to have a better survival rate in the general population.

AB - Purpose Adjuvant chemotherapy has been known as a standard treatment for patients with resected colon cancer. However, in elderly colon cancer patients, the characteristics of patients are heterogeneous with regard to life expectancy and comorbidities. Thus, with regard to the effectiveness of adjuvant chemotherapy for colon cancer, it is difficult to extrapolate data of clinical trials from the younger into the older general population. Methods Data for 382 elderly colon cancer patients were analyzed: 217 in Stage II and 165 in Stage III. The efficacy of adjuvant chemotherapy was evaluated in elderly colon cancer patients after a match by the propensity score method. Results For matched patients with Stage II colon cancer, there was no significant efficacy of adjuvant chemotherapy in the risk of death during all follow-up periods (P-value, 0.06-0.37). Though there was a tendency that the aadjuvant chemotherapy reduces the death rate during the follow-up periods, it was not statistically significant. In the case of Stage III, the adjuvant chemotherapy was significantly effective in matched patients for 5-year (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.30-0.90) and overall survival (HR, 0.56; 95% CI, 0.34-0.94). Conclusions Adjuvant chemotherapy for elderly patients with Stage II colon cancer is not effective, whereas elderly patients with Stage III with adjuvant chemotherapy appear to have a better survival rate in the general population.

UR - http://www.scopus.com/inward/record.url?scp=84876417551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876417551&partnerID=8YFLogxK

U2 - 10.1002/jso.23290

DO - 10.1002/jso.23290

M3 - Article

C2 - 23592499

AN - SCOPUS:84876417551

VL - 107

SP - 613

EP - 618

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 6

ER -